Literature DB >> 30614464

Dying to survive and cancer care in China.

Catherine Lucas.   

Abstract

Entities:  

Year:  2019        PMID： 30614464     DOI： 10.1016/S1470-2045(18)30921-5

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  5 in total

Review 1.  Unblocking Barriers of Access to Hepatitis C Treatment in China: Lessons Learned from Tianjin.

Authors:  Peiwen Zhang; Ran Guo; Jun Lian; Mengjia Zhi; Chengzhen Lu; Weishen Wu; Lihong Wang; Polin Chan; Zhongdan Chen; Jing Sun
Journal:  Ann Glob Health       Date:  2020-04-06       Impact factor: 2.462

2.  Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.

Authors:  Yanyan Liu; Huining Yi; Kexin Fang; Yuwen Bao; Xin Li
Journal:  Front Public Health       Date:  2022-07-22

3.  Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender.

Authors:  Pan Ran; Juan Li; Xingye Wu; Hao Yang; Jun Zhang
Journal:  Patient Prefer Adherence       Date:  2022-08-12       Impact factor: 2.314

4.  Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.

Authors:  Yichen Zhang; Huseyin Naci; Anita K Wagner; Ziyue Xu; Yu Yang; Jun Zhu; Jiafu Ji; Luwen Shi; Xiaodong Guan
Journal:  JAMA Netw Open       Date:  2022-08-01

Review 5.  Unlocking Access To Novel Medicines In China-A Review From A Health System Perspective.

Authors:  Yifan Diao; Mingshuang Li; Zhiran Huang; Jing Sun; Yoke Ling Chee; Yunali Liu
Journal:  Risk Manag Healthc Policy       Date:  2019-12-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.